Fusogenic pH sensitive liposomal formulation for rapamycin: Improvement of antiproliferative effect

References

• Akamatsu K. (2009). Development of a thermal neutron-sensitive liposome for a novel drug delivery system aiming for radio-chemo-concurrent cancer therapy. Radiat Phys Chem 78:1179–83
   Google Scholar
• Bae-Jump VL, Zhou C, Boggess JF, et al. (2010). Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment. Gynecol Oncol 119:579–85
   PubMed Web of Science ®Google Scholar
• Bae-Jump VL, Zhou C, Gehrig PA, et al. (2006). Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecol Oncol 100:487–94
   PubMedGoogle Scholar
• Bajoria R, Sooranna SR. (1998). Liposome as a drug carrier system: Prospects for safer prescribing during pregnancy: A review. Placenta 19:265–87
   Google Scholar
• Barenholz Y. (2001). Liposome application: Problems and prospects. Curr Opin Colloid Interface Sci 6:66–77
   Web of Science ®Google Scholar
• Cabanes A, Reig F, Garcia-Anton JM, Arboix M. (1998). Evaluation of free and liposome-encapsulated gentamycin for intramuscular sustained release in rabbits. Res Vet Sci 64:213–17
   PubMed Web of Science ®Google Scholar
• Chandaroy P, Sen A, Alexandridis P, Hui SW. (2002). Utilizing temperature-sensitive association of Pluronic F-127 with lipid bilayers to control liposome–cell adhesion. Biochim Biophys Acta (BBA) – Biomembr 1559:32–42
   PubMed Web of Science ®Google Scholar
• Cho EC, Lim HJ, Kim HJ, et al. (2009). Role of pH-sensitive polymer–liposome complex in enhancing cellular uptake of biologically active drugs. Mat Sci Eng C 29:774–8
   Google Scholar
• Costa LJ. (2007). Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin’s lymphoma. Cancer Treat Rev 33:78–84
   PubMed Web of Science ®Google Scholar
• Cukierman E, Khan DR. (2010). The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 80:762–70
   PubMed Web of Science ®Google Scholar
• Ghanbarzadeh S, Arami S. (2013a). Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. BioMed Res Int 2013:616810
   Google Scholar
• Ghanbarzadeh S, Arami S. (2013b). Formulation and evaluation of piroxicam transferosomal gel: An approach for penetration enhancement. J Drug Deliv Sci Technol 23:587–90
   Google Scholar
• Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. (2013a). Application of factorial designs and response surface methodology in formulation development of sirolimus liposome prepared by thin film hydration technique. BioImpacts 3:75–81
   PubMedGoogle Scholar
• Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. (2013b). The effects of lyophilization on the physico-chemical stability of sirolimus liposomes. Adv Pharm Bull 3:25–9
   PubMedGoogle Scholar
• Ghanbarzadeh S, Khorrami A, Pourmoazzen Z, Arami S. Plasma stable, pH-sensitive non-ionic surfactant vesicles simultaneously enhance antiproliferative effect and selectivity of Sirolimus. Pharm Dev Technol, in press-a
   Google Scholar
• Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. Sirolimus nano liposomes/optimization of sirolimus nano liposomes prepared by modified ethanol injection method using response surface methodology. Pharmind, in press-b
   Google Scholar
• Gondal JA, Preuss HG, Swartz R, Rahman A. (1993). Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur J Cancer 29:1536–42
   Google Scholar
• Hatziantoniou S, Dimas K, Georgopoulos A, et al. (2006). Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts. Pharmacol Res 53:80–7
   PubMed Web of Science ®Google Scholar
• Islambulchilar Z, Ghanbarzadeh S, Emami S, et al. (2012). Development and validation of an HPLC method for the analysis of sirolimus in drug products. Adv Pharm Bull 2:135–9
   PubMedGoogle Scholar
• Iyer AK, Singh A, Ganta S, Amiji MM. (2013). Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Del Rev 65:1784–802
   Google Scholar
• Jasinghe VJ, Xie Z, Zhou J, et al. (2008). ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol 49:985–97
   PubMedGoogle Scholar
• Jo S-M, Han M-R, Choi J-H, et al. (2007). Release property of pH-sensitive liposome composed of dioleoylphosphatidyl ethanoalmine and cholesteryl hemisuccinate. J Biotechnol 131:S49–52
   Google Scholar
• Kakegawa T, Nemoto A, Matsuda M, et al. (2003). Effect of rapamycin on NF-kappaB induction. Jpn J Antibiot 56:97–9
   PubMedGoogle Scholar
• Kim J-C, Kim J-D. (2002). Release property of temperature-sensitive liposome containing poly(N-isopropylacrylamide). Colloids Surf B Biointerfaces 24:45–52
   Web of Science ®Google Scholar
• Kono K, Igawa T, Takagishi T. (1997). Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim Biophys Acta (BBA) – Biomembr 1325:143–54
   PubMed Web of Science ®Google Scholar
• Law BK. (2005). Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol/Hematol 56:47–60.
   PubMed Web of Science ®Google Scholar
• Liang E, Hughes J. (1998). Characterization of a pH-sensitive surfactant, dodecyl-2-(1′-imidazolyl) propionate (DIP), and preliminary studies in liposome mediated gene transfer. Biochim Biophys Acta (BBA) – Biomembr 1369:39–50
   PubMed Web of Science ®Google Scholar
• MacDonald A, Scarola J, Burke J, Zimmerman J. (2000). Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22:B101–21
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Del Rev 65:71–9
   PubMed Web of Science ®Google Scholar
• Martin L-A, André F, Campone M, et al. (2013). mTOR inhibitors in advanced breast cancer: Ready for prime time? Cancer Treat Rev 39:742–52
   Google Scholar
• Meisner D, Mezei M. (1995). Liposome ocular delivery systems. Adv Drug Del Rev 16:75–93
   Web of Science ®Google Scholar
• Mi R, Ma J, Zhang D, et al. (2009). Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. J Genet Genomics 36:355–61
   PubMed Web of Science ®Google Scholar
• Nagata T, Toyota T, Ishigaki H, et al. (2007). Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine 25:4914–21
   PubMedGoogle Scholar
• Ogawa Y, Kodaka M, Okuno H. (2002). Trigger lipids inducing pH-dependent liposome fusion. Chem Phys Lipids 119:51–68
   PubMedGoogle Scholar
• Paghdal KV, Schwartz RA. (2007). Sirolimus (rapamycin): From the soil of Easter Island to a bright future. J Am Acad Dermatol 57:1046–50
   PubMed Web of Science ®Google Scholar
• Park SM, Kim MS, Park S-J, et al. (2013). Novel temperature-triggered liposome with high stability: Formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). J Control Release 170:373–9
   PubMed Web of Science ®Google Scholar
• Plas D, Thomas G. (2009). Tubers and tumors: Rapamycin therapy for benign and malignant tumors. Curr Opin Cell Biol 21:230–6
   PubMed Web of Science ®Google Scholar
• Rouf MA, Vural I, Renoir JM, Hincal AA. (2009). Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res 19:322–31
   Google Scholar
• Schreier H, Gonzalez-Rothi RJ, Stecenko AA. (1993). Pulmonary delivery of liposomes. J Control Release 24:209–23
   Web of Science ®Google Scholar
• Sharma A, Sharma US. (1997). Liposomes in drug delivery: Progress and limitations. Int J Pharm 154:123–40
   Web of Science ®Google Scholar
• Shen H, Wu G-j, Liu G-w, et al. (2009). Effects of rapamycin on the differentiation and function of macrophages in vitro. Agr Sci China 8:620–7
   Google Scholar
• Sudimack JJ, Guo W, Tjarks W, Lee RJ. (2002). A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta (BBA) – Biomembr 1564:31–7
   PubMed Web of Science ®Google Scholar
• Sun Q, Zheng Y, Liu Q, Cao X. (2008). Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation. Int Immunopharmacol 8:1854–8
   PubMedGoogle Scholar
• van Rossum HH, Romijn FPHTM, Smit NPM, et al. (2009). Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. Biochem Pharmacol 77:1206–12
   PubMed Web of Science ®Google Scholar
• Yagi N, Yano Y, Hatanaka K, et al. (2007). Synthesis and evaluation of a novel lipid–peptide conjugate for functionalized liposome. Bioorg Med Chem Lett 17:2590–3
   PubMedGoogle Scholar
• Yang F, Jin C, Jiang Y, et al. (2011). Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside. Cancer Treat Rev 37:633–42
   PubMed Web of Science ®Google Scholar
• Yuba E, Harada A, Sakanishi Y, et al. (2013). A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials 34:3042–52
   PubMed Web of Science ®Google Scholar
• Zagouri F, Sergentanis TN, Chrysikos D, et al. (2012). mTOR inhibitors in breast cancer: A systematic review. Gynecol Oncol 127:662–72
   PubMed Web of Science ®Google Scholar
• Zhou W, An X, Wang J, et al. (2012). Characteristics, phase behavior and control release for copolymer–liposome with both pH and temperature sensitivities. Colloids Surf Physicochem Eng Aspects 395:225–32
   Web of Science ®Google Scholar
• Zignani M, Drummond DC, Meyer O, et al. (2000). In vitro characterization of a novel polymeric-based pH-sensitive liposome system. Biochim Biophys Acta (BBA) – Biomembr 1463:383–94
   PubMed Web of Science ®Google Scholar